Amendment: SEC Form 10-K/A filed by PDS Biotechnology Corporation
$PDSB
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment No. 1)
(Mark One)
|
|
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the fiscal year ended December 31, 2025
|
|
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from ________to ________
Commission file number 001-37568
(Exact name of registrant as specified in its charter)
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices)
(800 ) 208-3343
(Registrant’s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
The
|
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller Reporting Company ☒ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error
to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive
officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The aggregate market value of the voting and non-voting common equity held by non-affiliates (without admitting that any person whose shares are not included in such calculation is an affiliate) of
the registrant as of June 30, 2025, was $60,145,221 , based on the closing price for shares of the registrant’s common stock as reported
on the Nasdaq Capital Market on that date.
The number of shares of the registrant’s common stock, par value $0.00033 per share, outstanding as of March 23, 2026 was 55,815,653 .
Explanatory Note
This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of PDS Biotechnology Corporation (the “Company,” “PDS Biotech”, “we”, “us”, or “our”)
for the fiscal year ended December 31, 2025, originally filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026 (the “Original Form 10-K”).
This Amendment is being filed to include the information required by Item 10 - “Directors, Executive Officers and Corporate Governance”, Item 11 - “Executive Compensation”, Item
12 - “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters”, Item 13 - “Certain Relationships and Related Transactions, and Director Independence” and Item 14 - “Principal Accountant Fees and Services” of
Part III of Form 10-K. The reference on the cover page of the Original Form 10-K to the incorporation by reference of portions of our definitive proxy statement into Part III of the Original Form 10-K is hereby deleted. Items 10, 11, 12, 13 and
14 of Part III of the Original Form 10-K are amended and restated in their entirety as set forth in this Amendment. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, in connection with this Amendment,
our Chief Executive Officer and Chief Financial Officer Rule 13a-14(a) certifications are included herein.
Except as described above, this Amendment does not modify or update disclosure in, or exhibits to, the Original Form 10-K. Furthermore, this Amendment does not change any
previously reported financial results, nor does it reflect events occurring after the filing date of the Original Form 10-K. Accordingly, this Amendment should be read in conjunction with the Original Form 10-K.
3
|
PAGE
|
|||
|
PART III
|
|||
|
Item 10
|
5
|
||
|
Item 11
|
15
|
||
|
Item 12
|
22
|
||
|
Item 13
|
25
|
||
|
Item 14
|
26
|
||
|
PART IV
|
|||
|
Item 15
|
27
|
||
|
28
|
|||
PART III
Board of Directors
Our Board is divided into three classes: Class A, Class B and Class C, with each class serving a three-year term. Vacancies on the Board may be filled only by persons elected
by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors that may serve on the Board, shall serve for the remainder of the full
term of that class and until the director’s successor is duly elected and qualified.
The following table sets forth information regarding our directors as of March 31, 2026:
|
Name
|
|
Age
|
|
(Class A − Term expiring at our annual meeting of stockholders in 2028)
|
|
|
|
Stephen Glover
|
|
66
|
|
Gregory Freitag, J.D., CPA
|
|
64
|
|
(Class B − Term expiring at our annual meeting of stockholders in 2026)
|
|
|
|
Kamil Ali-Jackson, Esq.
|
|
67
|
|
Ilian Iliev, Ph.D.
|
|
50
|
|
(Class C − Term expiring at our annual meeting of stockholders in 2027)
|
|
|
|
Frank Bedu-Addo, Ph.D.
|
|
61
|
|
Otis Brawley, M.D.
|
|
66
|
Mr. Glover has served on the Board since April 2019 and is the Chairman of the Board. Mr. Glover has over 40 years of business experience in biopharmaceuticals and life
sciences. Before founding ZyVersa, Mr. Glover was Co-Founder and Chief Business Officer of Coherus Biosciences where he was focused on business strategy, partnerships, product development efforts and capitalization of the company. Prior to
Coherus, he was the President of Insmed Therapeutic Proteins, a biosimilar company, as well as Chief Business Officer of Insmed Incorporated. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx
Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of Andrx Labs which developed and marketed products in metabolic diseases and Men’s Health, and Andrx
Therapeutics which was focused on development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and GlaxoSmithKline. Mr. Glover has
multifaceted experience in Fortune 100, start up, and entrepreneurial environments. He has demonstrated significant achievements in startups, large cap, and turnaround companies, with a focus on business strategy, commercial execution, product
development, business transformation and corporate development. He has completed over 25 life sciences transactions in licensing and M&A, raised over $500 million in capital, and created more than $7 billion in shareholder value. His
strategic and operational experience includes strategic planning, corporate development, operations management, product development, product marketing and sales management. Currently, Mr. Glover is Chairman of the Board of Directors of ZyVersa
Therapeutics and PDS Biotechnology. He is a member of the Board of Directors at BioGene Therapeutics and at the Coulter Foundation at the University of Miami. Previously Mr. Glover was Chairman of Ambrx Biopharma, overseeing its $2 billion
acquisition by Johnson & Johnson.
The Board believes Mr. Glover’s broad industry experience as well as his experience as a founder and strategic leader provides him with the qualifications and skills to serve as a director.
Mr. Freitag has served on the Board since March 2019. Mr. Freitag currently serves as a member of the board of directors of ZyVersa
Therapeutics (Nasdaq: ZVSA), a clinical-stage specialty biopharmaceutical company focused on developing drugs to treat inflammatory and renal diseases. Mr. Freitag served as Special Counsel for Axogen, Inc. (Nasdaq: AXGN) until his retirement in
April 2021, its General Counsel from September 2011 to December 2019, Chief Financial Officer from September 2011 to May 2014 and August 2015 to March 2016 and Senior Vice President of Business Development at Axogen from May 2014 until October
2018. Mr. Freitag was also a member of the Axogen, Inc. Board of Directors from 2011 to 2024. Axogen, Inc. is a leading regenerative medicine company dedicated to peripheral nerve repair. Mr. Freitag was Chief Executive Officer, Chief Financial
Officer and a board member from June 2010 through September 2011 of LecTec Corporation, an intellectual property licensing and holding company that merged with Axogen in September 2011. Mr. Freitag is a principal of FreiMc, LLC, a healthcare and
life science consulting and advisory firm he founded that provides strategic guidance and business development services. Prior to founding FreiMc, Mr. Freitag was a Director of Business Development at Pfizer Health Solutions, a former subsidiary
of Pfizer, Inc. and worked for Guidant Corporation in their business development group. Prior to Guidant Corporation, Mr. Freitag was the Chief Executive Officer of HTS Biosystems, a biotechnology tools start-up company and was the Chief
Operating Officer, Chief Financial Officer and General Counsel of Quantech, Ltd. Prior to Quantech, Mr. Freitag practiced corporate law in Minneapolis, Minnesota.
The Board believes that Mr. Freitag’s leadership, legal, corporate governance and accounting experience and knowledge, as well as his
familiarity with the life sciences industry and PDS Biotech, provide him with the qualifications and skills to serve as a director.
Ms. Ali-Jackson has served on the Board since February 2020. Ms. Ali-Jackson brings four decades of life sciences industry experience
with public and private specialty pharmaceutical, biotech, and biopharmaceutical companies to PDS Biotech. Ms. Ali-Jackson has extensive domestic and international experience with strategic alliances, drug development and commercialization
collaborations, and M & A transactions. Ms. Ali-Jackson is the co-founder of Aclaris Therapeutics, Inc. and served as its Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary since its inception in 2012 until her retirement
in January 2022. In addition, Ms. Ali-Jackson co-founded and successfully transitioned several specialty pharmaceutical and biopharmaceutical companies through multi-million-dollar acquisitions by global life sciences companies. In 2011, Ms.
Ali-Jackson also co-founded NeXeption, Inc., a biopharmaceutical assets management company and was legal counsel for the company and its affiliated companies from 2011 until 2020. She has served as legal counsel and as a licensing business
executive for a number of life sciences companies, including Merck & Co. Inc. and Dr. Reddy’s Laboratories Ltd. Ms. Ali-Jackson currently serves on the board of directors, audit, finance and compensation committees for Rigel Pharmaceuticals,
Inc., a publicly traded biotechnology company. She has also served on several nonprofit boards and currently serves on the board of trustees of Princeton University and as the Chair of the East Bradford Township Zoning Hearing Board. Ms.
Ali-Jackson received her J.D. from Harvard Law School and Bachelor of Arts in politics from Princeton University.
The Board believes that Ms. Ali-Jackson’s leadership, legal, transactional, compliance and corporate governance expertise and
knowledge, as well as her experience as an executive officer, legal counsel, and co-founder in the life sciences industry, provide her with the qualifications and skills to serve as a director.
Dr. Iliev has served on the Board since April 2020. Dr. Iliev is Chief Executive Officer of EMV Capital PLC (previously NetScientific PLC), a London Stock Exchange listed
company investing in deep tech and life sciences in the UK and internationally. Dr. Iliev founded EMV Capital in 2018, and the company was acquired by NetScientific PLC in 2020. Previously, Dr. Iliev served as the Chief Executive Officer and
co-founder of CambridgeIP Ltd, a Cambridge, UK based boutique strategy consultancy focused on technology and IP commercialization. Dr. Iliev serves on the board of directors of several EMV Capital portfolio companies in the life sciences and
deeptech space. Dr. Iliev holds a Ph.D. from Cambridge University’s Judge Business School, focused on venture capital business models in emerging economies. He received a Master of Commerce in Economics, and a Bachelor of Arts in Politics,
Economics and International Relations from the University of Witwatersrand, South Africa.
The Board believes Dr. Iliev’s venture capital and high-growth company experience provides him with the qualifications and skills to serve as a director.
Dr. Bedu-Addo has served as director, President and Chief Executive Officer of PDS Biotech since March 2019. Dr. Bedu-Addo is a
veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the oversight, development and implementation of both operational and drug development strategies in both large
organizations and emerging biotechnology companies. Dr. Bedu-Addo was a member of the senior executive team at KBI BioPharma, Inc. As Vice President of Drug Development, he oversaw all operations including business development, drug
development/manufacturing and profit and loss. Before his tenure at KBI, he successfully started and managed Cardinal Health’s East Coast biotechnology drug development and manufacturing operations. Prior to Cardinal Health, Dr. Bedu-Addo was an
Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions, he contributed to the development of numerous drugs, including antiviral and anticancer products. Dr.
Bedu-Addo obtained both his M.S. in Chemical Engineering and Ph.D. in Pharmaceutics from the University of Pittsburgh.
The Board believes that Dr. Bedu-Addo’s perspective and experience as our President and CEO, as well as his depth of operating and
senior management experience in the pharmaceuticals industry and educational background, provide him with the qualifications and abilities to serve as a director.
Dr. Brawley has served on the Board since November 2020. Dr. Otis Brawley, M.D. is a renowned oncologist and a seasoned pharmaceutical director who has served on several
boards including the boards of companies developing and commercializing oncology products. Dr. Brawley is currently the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. Dr. Brawley served as the Chief
Medical and Scientific Officer at the American Cancer Society from 2007 through 2018, and is a former member of the FDA Oncologic Drug Advisory Committee (ODAC) and the National Cancer Institute’s (NCI) Board of Scientific Counselors. Formerly,
Dr. Brawley was a professor in the Department of Hematology and Oncology at the Emory University School of Medicine. He was also previously a senior investigator at the National Institute of Health (NIH) and NCI Dr. Brawley is currently a
director at Jackson Laboratories, a nonprofit biomedical research center focused on developing genomic solutions to disease including personalized, tailored therapeutics for individual cancers; formerly, he was a Director for the Theragenics
Corporation, a publicly traded company with commercialized medical devices for brachytherapy, surgery and wound closure. Dr. Brawley is also on the board of Incyte Corporation, a biopharmaceutical company focused on discovery, development and
commercialization of proprietary therapeutics, Agilent Technologies, an analytical instrumentation development and manufacturing company, and Lyell Immunopharma, Inc., a private biotechnology company. Dr. Brawley received an M.D. from the
University of Chicago, Pritzker School of Medicine. He completed an internal medicine residency at Case-Western Reserve University and a fellowship in medical oncology at the NCI. He is board certified in internal medicine and medical oncology.
In 2013, he was the recipient of a Special Recognition Award from the American Society of Clinical Oncology. In 2019 he was given the American Medical Association Distinguished Service Award. Dr. Brawley is a Master of the American College of
Physicians, a Fellow of the Royal College of Physicians (London), and an elected member of the U.S. National Academy of Medicine.
The Board believes that Dr. Brawley’s expertise in the field of Oncology as well as his experience on public company and non-profit boards and his educational background
provide him with the qualifications and abilities to serve as a director.
Executive Officers
The following table sets forth information regarding our executive officers as of March 31, 2026:
|
Name
|
|
Age
|
|
Position
|
|
Frank Bedu-Addo, Ph.D.
|
|
61
|
|
President, Chief Executive Officer, Principal Executive Officer and Director
|
|
Gregory L. Conn, Ph.D.
|
|
71
|
|
Chief Scientific Officer
|
|
Kirk Shepard, M.D.
|
|
75
|
|
Chief Medical Officer
|
|
Lars Boesgaard
|
56
|
|
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
|
|
|
Stephan Toutain
|
|
60
|
|
Chief Operating Officer
|
|
Spencer Brown
|
|
56
|
|
Senior Vice President, General Counsel, Corporate Secretary, and Compliance Officer
|
Biographies for each of our executive officers is provided below.
Frank Bedu-Addo, Ph.D.
Please see Dr. Bedu-Addo’s biography on under the section “Board of Directors” above.
Gregory L. Conn, Ph.D.
Dr. Conn was a founding member of the PDS Biotech team in 2005 as Chief Scientific Officer and continues to serve PDS Biotech in that
role. He has more than 40 years of drug-development expertise, including development of antiviral and anticancer drugs through to commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and
Ph.D., discovering novel angiogenic molecules in the human brain. Dr. Conn started his pharmaceutical career at Merck, Sharpe, and Dohme, where he continued his work on novel angiogenic factors, discovering and characterizing the VEGF family of
growth factors, work which led to the development and commercialization of the anti-cancer drug Avastin. He was later a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular
Biology and Drug Discovery departments. Dr. Conn subsequently became a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization, where he
supervised the analytical development teams responsible for drug characterization, method development and drug stability studies, and program teams responsible for developing drug manufacturing processes. Dr. Conn has expertise across all phases
of the drug development process, including FDA and regulatory requirements, and is the co-inventor of twelve drug patents.
Kirk Shepard, M.D.
Dr. Shepard has served as Chief Medical Officer of PDS Biotech since January 2024. Prior to PDS Biotech, Dr. Shepard was Chief Medical Officer, Senior Vice President and Head
of Global Medical Affairs Oncology at Eisai Inc. Dr. Shepard has served in leadership positions at companies that have included Takeda, Boehringer Ingelheim, Baxter, and Baxalta. Dr. Shepard’s experience in multiple therapeutic areas includes
operational and strategic product development from Phases 1 through 4 and the diverse disciplines of commercialization, clinical development, and medical affairs, such as real world evidence (RWE), health economics outcomes research (HEOR) &
patient access, Investigator-Initiated Research, field-based medical teams (MSLs), leading compliance and SOP/policy efforts, PV/safety, medical communication, publications, digital strategy & initiatives, patient advocacy, and public
relations. Dr. Shepard received his fellowship Oncology and Hematology training at the University of Chicago Medical Center and then was on the Hematology-Oncology staff at the Cleveland Clinic Foundation before transitioning to the
pharmaceutical industry. In 2015, he was selected as one of the 100 Most Inspiring People in the Pharmaceutical Industry (PharmaVOICE). He is a co-founder of the Medical Affairs Professional Society (MAPS), and in 2016-17 he was President of
MAPS. He received his BA from Cornell University in Ithaca, NY, where he was on the varsity football team.
Lars Boesgaard
Mr. Boesgaard has served as Chief Financial Officer and Principal Financial and Accounting Officer of PDS Biotech since December 2023. Prior to joining PDS Biotech, he served
as CFO of AM-Pharma B.V. from September 2021 to August 2023. Mr. Boesgaard also served as CFO of Columbia Care from August 2018 to August 2021, where he completed key transactions, including an IPO/reverse merger resulting in a $120 million
capital infusion and raising $200 million in public equity and debt offerings. Mr. Boesgaard was also previously the Vice President, CFO of Roka Bioscience from November 2015 to July 2018 and held several other senior finance positions with
publicly traded companies, including Insulet Corporation, Alexion Pharmaceuticals, and Novo Nordisk A/S. Mr. Boesgaard holds a Bachelor of Science in Business Administration from the Copenhagen Business School and a Master of Business
Administration from the Richard Ivey School of Business, Western University, Ontario, Canada.
Stephan Toutain
Mr. Toutain joined PDS Biotech in May 2024 as Chief Operating Officer. He brings over 30 years of operational experience in the life sciences industry from drug development,
general management, operations, commercial development, market access and sales and marketing leadership with prior expertise in oncology and orphan drugs markets globally. Before joining PDS Biotech, Mr. Toutain served as Chief Operating Officer
at Anavex Life Sciences and Chief Commercial Officer at Interleukin Genetics. He also worked with Alnylam Pharmaceuticals to build its early access program. In addition, Mr. Toutain led Global Commercial Development for Sarepta Therapeutics and
served as General Manager for Alexion Pharmaceuticals in Europe. He has also held various U.S. commercial, marketing and product management positions with Celgene Corporation and Johnson & Johnson. Mr. Toutain received a Master of Business
Administration from the University of North Carolina Kenan-Flagler Business School, and a Master of Engineering in Biotechnology from the University of Nancy II in France.
Spencer Brown
Mr. Brown has served as Senior Vice President, General Counsel and Corporate Secretary of PDS Biotech since June 2022 and has served as Compliance Officer since October 2023.
Mr. Brown previously served as Vice President, Legal Affairs from January 2018 to January 2022 and as Senior Vice President, Legal Affairs and Compliance Officer from January 2022 to May 2022, for Aclaris Therapeutics, Inc. (Nasdaq: ACRS). Prior
to joining Aclaris Therapeutics, Inc., Mr. Brown worked nearly eight years at GE Healthcare as Senior Commercial Counsel for the Life Sciences Core Imaging business in Princeton, New Jersey. Prior to that, Mr. Brown spent almost ten years at
AstraZeneca Pharmaceuticals in Wilmington, Delaware where he provided legal support for most of the company’s therapeutic areas at some point during his tenure. Mr. Brown has over two decades of in-house experience in the life sciences industry.
Mr. Brown began his legal career as an associate at Skadden, Arps, Slate, Meagher & Flom. Mr. Brown earned his bachelor’s degree at Princeton University and obtained his juris doctorate degree from the University of Pennsylvania Carey School
of Law.
Independence of the Board of Directors
As required under the Nasdaq listing standards, a majority of the members of a listed company’s board of directors must qualify as
“independent,” as affirmatively determined by the board of directors. The Board consults with our counsel to ensure that the Board’s determinations are consistent with relevant securities and other laws and regulations regarding the definition of
“independent,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.
The Board has undertaken a review of the independence of our directors and has determined that all of our directors, except Frank
Bedu-Addo, Ph.D. and Ilian Iliev, Ph.D., are independent within the meaning of Section 5605(a)(2) of the Nasdaq Stock Market listing rules. Dr. Bedu-Addo is not an independent director under these rules because he is our President and Chief
Executive Officer, and the Board has determined that Dr. Iliev is not an independent director because of his relationship with NetScientific plc, a current stockholder of the Company.
Board Leadership Structure
The Board has appointed Mr. Stephen Glover as Chairman of the Board. The Chairman has the authority, among other things, to preside over Board meetings, to set meeting agendas and
to perform all other duties delegated to him from time to time by the Board. We believe that separation of the positions of Board Chairman and Chief Executive Officer reinforces the independence of the Board in its oversight of our business and
affairs. In addition, we believe that having an independent Chairman creates an environment that is more conducive to objective evaluation and oversight of management’s performance, increasing management accountability and improving the ability
of the Board to monitor whether management’s actions are in our best interests and the best interests of our stockholders. As a result, we believe that having an independent Chairman can enhance the effectiveness of the Board as a whole.
Family Relationships
There are no family relationships among any of our directors or executive officers.
Board Diversity
The Board is committed to having a diversified board, including diversity of thought, background and experience.
Role of the Board in Risk Oversight
One of the Board’s key functions is informed oversight of our risk management process. The Board does not have a standing risk management committee, but rather
administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. Our Board is responsible for monitoring and
assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for us. Our Audit Committee has the responsibility to review and discuss with management and KPMG LLP, the Company’s independent auditors,
as appropriate, our guidelines and policies with respect to risk assessment and risk management, including our major financial risk exposures and the steps taken by management to monitor and control these exposures , including as it concerns risks from cybersecurity threats. In general, we seek to address cybersecurity risks through a cross-functional approach that is focused on
preserving the confidentiality, integrity, and availability of the information that we collect and store by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur. Our
Nominating and Corporate Governance Committee is responsible for developing our corporate governance principles, and periodically reviews these principles and their application. Our Compensation Committee reviews our practices and policies of
employee compensation as they relate to risk management and risk-taking incentives, to determine whether such compensation policies and practices are reasonably likely to have a material adverse effect on us.
Meetings of the Board of Directors
Each director is expected to make reasonable efforts to attend all Board and applicable committee meetings. Attendance is taken into
account by the Nominating and Corporate Governance Committee and the Board when they assess directors for re-nomination to the Board. Each director is also expected to attend our annual stockholder meetings, and six of our current directors
attended the 2025 Annual Meeting of Stockholders. The Board met eleven (11) times during the year ended December 31, 2025. All directors attended at least 75% of the aggregate number of meetings of the Board and of the committees on which they
served during 2025 or the portion thereof for which they were directors or committee members.
Information Regarding Committees of the Board of Directors
The Board has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following
table provides membership information for each of these standing Board committees. From time to time, our Board and committees also take action by written consent without a meeting. Each of our Board committees has authority to engage legal
counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities.
|
Name
|
Audit
|
Compensation
|
Nominating
and
Corporate
Governance
|
|||||||||
|
Stephen Glover
|
X |
|
X
|
*
|
||||||||
|
Kamil Ali-Jackson, Esq.
|
X |
|
X |
|
X
|
*
|
||||||
|
Frank Bedu-Addo, Ph.D.
|
||||||||||||
|
Otis Brawley, M.D.
|
||||||||||||
|
Gregory Freitag, J.D., CPA
|
X
|
*
|
X |
|
||||||||
|
Ilian Iliev, Ph.D.
|
||||||||||||
|
*
|
Committee Chairperson
|
Audit Committee
Our Audit Committee currently consists of Mr. Freitag, Mr. Glover and Ms. Ali-Jackson, each of whom satisfies the independence requirements under The Nasdaq Capital Market
listing standards and Rule 10A-3(b)(1) of the Exchange Act. The chairperson of our Audit Committee is Mr. Freitag, whom our Board has determined to be an “audit committee financial expert” within the meaning of SEC regulations. Each member of our
Audit Committee can read and understand fundamental financial statements in accordance with Audit Committee requirements. In arriving at this determination, the Board has examined each Audit Committee member’s scope of experience and the nature
of their employment in the corporate finance sector. PDS Biotech’s Audit Committee held four (4) meetings in 2025.
The primary purpose of our Audit Committee is to assist the Board in the oversight of the integrity of our accounting and financial reporting process, the audits of our
financial statements, and our compliance with legal and regulatory requirements. The functions of our Audit Committee include, among other things:
|
•
|
hiring an independent registered public accounting firm to conduct the annual audit of our financial statements and monitoring its independence and performance;
|
| • |
reviewing and approving the planned scope of the annual audit and the results of the annual audit;
|
| • |
pre-approving all audit services and permissible non-audit services provided by our independent registered public accounting firm;
|
| • |
reviewing the significant accounting and reporting principles to understand their impact on our financial statements;
|
| • |
reviewing our internal financial, operating and accounting controls with management and our independent registered public accounting firm;
|
| • |
reviewing with management and our independent registered public accounting firm, as appropriate, our financial reports, earnings announcements and our compliance with legal and
regulatory requirements;
|
| • |
reviewing potential conflicts of interest under and violations of our Code of Conduct;
|
With respect to reviewing and approving related-party transactions, our Audit Committee reviews related-party transactions for potential conflicts of interest or other
improprieties. Under SEC rules, related-party transactions are those transactions to which we are or may be a party in which the amount involved exceeds $120,000, and in which any of our directors or executive officers or any other related person
had or will have a direct or indirect material interest, excluding, among other things, compensation arrangements with respect to employment and board membership. Our Audit Committee could approve a related-party transaction if it determines that
the transaction is in our best interests. Our directors are required to disclose to the committee or the full Board any potential conflict of interest or personal interest in a transaction that our board is considering. Our executive officers are
required to disclose any potential conflict of interest or personal interest in a transaction to the Audit Committee. We also poll our directors and executive officers on an annual basis with respect to related-party transactions and their
service as an officer or director of other entities. Whenever possible, the transaction should be approved in advance and if not approved in advance, must be submitted for ratification as promptly as practical.
The Board has adopted a charter for the Audit Committee that complies with SEC and Nasdaq Stock Market listing rules. The charter is available on our website at www.pdsbiotech.com.
Compensation Committee
Our Compensation Committee currently consists of Mr. Glover and Ms. Ali-Jackson, each of whom our Board has determined to be independent under the Nasdaq listing standards
and a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act. The chairperson of our Compensation Committee is Stephen Glover. PDS Biotech’s Compensation Committee held four (4) meeting in 2025.
The primary purpose of our Compensation Committee is to assist the Board in exercising its responsibilities relating to compensation of our executive officers and employees
and to administer our equity compensation and other benefit plans. In carrying out these responsibilities, this committee reviews all components of executive officer and employee compensation for consistency with its compensation philosophy, as
in effect from time to time. The functions of our Compensation Committee include, among other things:
| • |
designing and implementing competitive compensation policies to attract and retain key personnel;
|
| • |
reviewing and formulating policy and determining the compensation of our executive officers and employees;
|
| • |
reviewing and recommending to the Board the compensation of our directors;
|
| • |
administering our equity incentive plans and granting equity awards to our employees and directors under these plans;
|
| • |
if required from time to time, reviewing with management our disclosures under the caption “Executive Compensation” and recommending to the full board its inclusion in our periodic
reports to be filed with the SEC;
|
| • |
if required from time to time, preparing the report of the Compensation Committee to be included in our annual proxy statement;
|
| • |
engaging advisors it deems appropriate to assist with its duties; and
|
| • |
reviewing and evaluating, at least annually, our Compensation Committee’s charter.
|
The Compensation Committee may review competitive compensation data to inform the Compensation Committee’s decisions on overall
compensation of our executive officers and directors, as well as specific pay elements. The Compensation Committee applies judgment and discretion in establishing targeted pay levels, taking into account factors such as Company, business and
individual performance, experience, scope of responsibility, criticality and skill sets, leadership potential and succession planning.
The Board has adopted a charter for the Compensation Committee that complies with SEC and Nasdaq Stock Market listing rules. The
charter is available on our website at www.pdsbiotech.com.
Compensation Committee Interlocks and Insider Participation
No member of our Compensation Committee has ever been an executive officer or employee of ours. None of our officers currently serve, or served during 2025, on the
compensation committee or board of directors of any other entity that has one or more officers serving as a member of the Board or Compensation Committee.
Nominating and Corporate Governance Committee
Our Nominating and Corporate Governance Committee currently consists of Ms. Ali-Jackson and Mr. Freitag, each of whom our Board has
determined to be independent under the Nasdaq listing standards. The chairperson of our Nominating and Corporate Governance Committee is Ms. Ali-Jackson. Our Nominating and Corporate Governance Committee held four (4) meetings in 2025.
The primary purpose of our Nominating and Corporate Governance Committee is to assist the Board in promoting our best interests and the best interests of our stockholders
through the implementation of sound corporate governance principles and practices. The functions of our Nominating and Corporate Governance Committee include, among other things:
| • |
identifying, reviewing and evaluating candidates to serve on our board;
|
| • |
determining the minimum qualifications for service on our board;
|
| • |
developing and recommending to our board an annual self-evaluation process for our board and overseeing the annual self-evaluation process;
|
| • |
developing, as appropriate, a set of corporate governance principles, and reviewing and recommending to our board any changes to such principles; and
|
| • |
periodically reviewing and evaluating our Nominating and Corporate Governance Committee’s charter.
|
The Board has adopted a charter for the Nominating and Corporate Governance Committee that complies with SEC and Nasdaq Stock Market listing rules. The charter is available
on our website at www.pdsbiotech.com.
While the Nominating and Corporate Governance Committee does not have a formal diversity policy, the Nominating and Corporate Governance Committee recommends candidates based
upon many factors, including the diversity of their business or professional experience, the diversity of their background and their array of talents and perspectives. We believe that the Nominating and Corporate Governance Committee’s existing
nominations process is designed to identify the best possible nominees for the Board, regardless of the nominee’s gender, racial background, religion, or ethnicity. The Nominating and Corporate Governance Committee identifies candidates through a
variety of means, including recommendations from members of the Board and suggestions from our management, including our executive officers. In addition, the Nominating and Corporate Governance Committee considers candidates recommended by third
parties, including stockholders. The Nominating and Corporate Governance Committee gives the same consideration to candidates recommended by stockholders as those candidates recommended by members of our Board. Nominees should have a reputation
for integrity, honesty and adherence to high ethical standards, should have demonstrated business acumen, experience and ability to exercise sound judgments in matters that relate to our current and long-term objectives, should be willing and
able to contribute positively to our decision-making process, should have a commitment to understand PDS Biotech and our industry and to regularly attend and participate in meetings of the Board and its committees, should have the interest and
ability to understand the sometimes conflicting interests of the various constituencies of PDS Biotech, which include stockholders, employees, customers, creditors and the general public, and to act in the interests of all stockholders, should
not have, nor appear to have, a conflict of interest that would impair the nominee’s ability to represent the interests of all our stockholders and to fulfill the responsibilities of a director. Nominees shall not be discriminated against on the
basis of race, religion, national origin, sex, sexual orientation, disability or any other basis proscribed by law. The value of diversity on the Board should be considered. The Nominating and Corporate Governance Committee considers director
candidates recommended by stockholders. The Nominating and Corporate Governance Committee does not intend to alter the manner in which it evaluates candidates, including the criteria set forth above, based on whether or not the candidate was
recommended by a stockholder.
Stockholder Communications with Board of Directors
We do not have a formal process related to stockholder communications with the Board. However, we strive to ensure that the views of stockholders are heard by the Board or
individual directors, as applicable, and that appropriate responses are provided to stockholders in a timely manner. We believe our responsiveness to stockholder communications to the Board has been excellent. If you wish to send a communication
to the Board, its chair or the chair of any Board committee, please send your communication to Frank Bedu-Addo, Ph.D., our Chief Executive Officer, at PDS Biotechnology Corporation at 303A College Road East, Princeton, NJ 08540, who will forward
all appropriate communications as requested.
Delinquent Section 16(a) Reports
Section 16(a) of the Exchange Act, requires our officers (as defined under Section 16(a) of the Exchange Act), directors and persons who own greater than 10% of a registered class
of our equity securities to file reports of ownership and changes in ownership with the SEC. Based solely on review of the copies of Forms 3 and 4 and amendments thereto filed with the SEC during the fiscal year ended December 31, 2025 and Forms
5 and amendments thereto filed with the SEC with respect to such fiscal year, or written representations that no Forms 5 were required, we believe that there were no instances where our officers, directors and greater than ten percent beneficial
owners failed to file on a timely basis all Section 16(a) filing requirements during the fiscal year ended December 31, 2025, other than the filing of a Form 4 on July 25,2025, for each of Lars Boesgaard, Stephan Toutain, Frank Beddu-Addo, Ph.D.,
Spencer D. Brown, Kirk Shephard and Gregory Conn, which were filed late due to administrative oversights.
Code of Business Conduct and Ethics for Employees, Executive Officers and Directors
We have adopted a Code of Conduct, applicable to all of our employees, executive officers and directors. The Code of Conduct is available on our website at www.pdsbiotech.com. The Nominating and Corporate Governance Committee is responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers or
directors. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website within four business days of such amendment or waiver.
Anti-Hedging/Anti-Pledging Policy
Pursuant to our insider trading policy ,
our employees, executive officers and directors may not (a) hold our securities in a margin account, (b) pledge our securities as collateral for a loan or (c) enter into hedging or monetization transactions or similar arrangements with respect to
our securities, in each case without the advance approval of our compliance officer.
As a smaller reporting company, we are not required to include a Compensation Discussion and Analysis (CD&A) under Item 402(b) of
Regulation S-K and have elected to comply with the scaled disclosure requirements that apply to smaller reporting companies.
Summary Compensation Table
The following table sets forth information for the years ended December 31, 2025 and December 31, 2024 concerning compensation of (i) all
individuals serving as our principal executive officer for the year ended December 31, 2025, (ii) our two most highly compensated executive officers, other than our principal executive officer, who were serving as executive officers as of
December 31, 2025 and (iii) up to two of our most highly compensated executive officers, other than our principal executive officer, that were not serving as executive officers as of December 31, 2025. We refer to these executives as the named
executive officers. In accordance with the rules promulgated by the SEC, certain columns relating to information that is not applicable have been omitted from this table.
|
Year
|
Salary
$
|
Bonus
$
|
Option
Awards(1)
$
|
All Other
Compensation
$(2)
|
Total
$
|
||||||||||||||||||
|
Frank Bedu-Addo, Ph.D.
|
2025
|
615,322
|
-
|
193,500
|
19,485
|
828,307
|
|||||||||||||||||
|
Chief Executive Officer
|
2024
|
597,000
|
-
|
1,647,000
|
19,169
|
2,263,569
|
|||||||||||||||||
|
Kirk Shepard, M.D. (3)
|
2025
|
463,500
|
-
|
193,500
|
20,318
|
677,318
|
|||||||||||||||||
|
Chief Medical Officer
|
2024
|
426,346
|
45,000
|
840,000
|
14,250
|
1,325,596
|
|||||||||||||||||
|
Stephan Toutain (4)
|
2025
|
463,500
|
-
|
193,500
|
16,629
|
673,629
|
|||||||||||||||||
|
Chief Operating Officer
|
2024
|
300,000
|
30,038
|
600,000
|
9,750
|
939,788
|
|||||||||||||||||
|
(1)
|
Amounts shown in this column do not reflect actual compensation received by the named executive officers. The amounts reflect the grant date fair value of stock option awards and are
calculated in accordance with the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718-Stock Compensation, and assume no forfeiture rate derived in the calculation of the grant
date fair value of these awards. Assumptions used in calculating the value of these awards are included in Note 8, “Stock Based Compensation” in the notes to the Company’s financial statements included in the Company’s Annual Report on
Form 10-K for the year ended December 31, 2025. The executive will only realize compensation to the extent the trading price of the Company’s common stock is greater than the exercise price of such stock options at the time such options
are exercised.
|
|
(2)
|
“All Other Compensation” consists of the Safe Harbor 401(k) match under the Company’s 401(k) plan
|
|
(3)
|
Dr. Shepard’s employment start date with the Company was January 22, 2024.
|
|
(4)
|
Mr. Toutain’s employment start date with the Company was May 1, 2024.
|
Narrative to Summary Compensation Table
Key Performance Factors in Determining Executive Compensation
Because the biopharmaceutical industry is characterized by a very long product development cycle, including a lengthy R&D period and a rigorous regulatory approval
process, including the requirements for multiple phases of human testing and the need to meet a significant number of other government requirements, many of the traditional financial performance metrics, such as product sales, revenues and
profits, used to evaluate successful performance are inappropriate for a biopharmaceutical company with a continued development focus, such as PDS Biotech. Instead, the specific performance our Compensation Committee considers when evaluating the
compensation of our named executive officers include:
| • |
key R&D achievements
|
| • |
initiation and progress of clinical trials for our product candidates;
|
| • |
achievement of regulatory milestones;
|
| • |
new business initiatives including financings;
|
| • |
our progress in building out key functions and managing our growth while maintaining a high-performing organization and culture; and
|
| • |
increasing shareholder value.
|
Annual corporate goals are proposed by our senior leadership team at the beginning of each year and approved by our Board of Directors. During the first quarter of each year,
our Compensation Committee, with the input of the senior leadership team, evaluates our corporate performance for the prior year against the corporate goals set for that year, and, taking into account other corporate achievements and
developments, recommends a corporate performance rating to be approved by our Board of Directors.
During the first quarter of each year, our Compensation Committee typically evaluates compensation levels of our executive officers, for such year, including the amount of
each executive officer’s base salary, target annual bonus and annual equity awards, taking into consideration the compensation paid by our peer group, our prior year’s overall corporate performance against the established corporate goals, as well
as each individual executive officer’s contributions to achievement of such corporate goals, individual performance and the other factors described above, in making compensation recommendations to our Board of Directors. Our Board of Directors
considers these recommendations in determining the compensation for our executive officers for the applicable year.
Elements of Executive Compensation
The compensation of our named executive officers consists of base salary, annual cash bonuses and equity awards, as well as employee benefits that are made available to our
salaried employees generally. Our named executive officers are also entitled to compensation and benefits upon certain terminations of employment, including following a change of control transaction, as described under “Employment Agreements”
below.
On March 14, 2022, we entered into an amended and restated employment agreement with Dr. Bedu-Addo. We entered into employment agreements with Dr. Shepard and Mr. Toutain
upon their commencement of employment in a substantially similar form as Dr. Bedu-Addo’s employment agreement in order to provide consistency among our executive officers. The terms of the employment agreements are summarized below. The form of
employment agreement was reviewed by our Board of Directors and by the Compensation Committee’s independent compensation consultant to determine whether its provisions are consistent with the employment agreements of our benchmarking peer group.
In March 2022, the form of employment agreement was approved by the Compensation Committee, both for use as a form and with respect to the specific terms applicable to each executive officer. Although we believe that each company in our
benchmarking peer group understandably has forms of employment agreements that are different from ours, we believe key employment contract provisions covering our executive officers are in line with market practice and provide terms designed to
attract and retain executive officers.
Base Salaries
We pay our named executive officers a base salary to compensate them for the satisfactory performance of services rendered to the Company. The base salary payable to each
named executive officer is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. Base salaries for our named executive officers have generally been set at levels deemed
necessary to attract and retain individuals with superior talent and were originally established in each named executive officer’s employment agreement.
Dr. Bedu-Addo received a base salary of $615,322 in 2025 and $597,000 in 2024. Dr. Shepard received a base salary of $463,500 in 2025 and $450,000 in 2024 (pro-rated for the
2024 calendar year based on his employment start date in 2024). Mr. Toutain received a base salary of $463,500 in 2025 and $450,000 in 2024 (pro-rated for the 2024 calendar year based on his employment start date in 2024).
Performance Bonuses
We offer our named executive officers the opportunity to earn discretionary annual cash bonuses to compensate them for attaining
short-term company and individual performance goals, subject to continued employment through the applicable payment date of such bonus. Each named executive officer has an annual target bonus that is expressed as a percentage of his annual base
salary. The 2025 target bonus amounts for each of Dr. Bedu-Addo, Dr. Shepard and Mr. Toutain were as follows:
|
Executive
|
|
2025 Target Bonus
|
|
Frank Bedu-Addo, Ph.D.
|
|
Up to 55% of Base Salary
|
|
Kirk Shepard, M.D.
|
|
Up to 40% of Base Salary
|
|
Stephan Toutain
|
|
Up to 40% of Base Salary
|
The Compensation Committee retains the discretion to reduce or eliminate any discretionary annual cash bonuses that might otherwise be payable, including in order to conserve cash
for operations or capital expenditures supporting future growth in furtherance of our strategic priorities, or for other business opportunities that could either preserve or enhance stockholder value. Pursuant to this discretion, the Compensation
Committee determined not to pay any discretionary annual cash bonuses to our named executive officers with respect to the 2025 performance year. The Compensation Committee’s decision was not a reflection of the individual performance of any of
our NEOs.
Equity Compensation
PDS Biotechnology Corporation 2014 Equity Incentive Plan
In 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan (the “Original Plan”) pursuant to which the Company was
permitted to grant up to 91,367 shares subject to awards of incentive stock options (“ISOs”), non-qualified stock options and restricted stock units, subject to increases as hereafter described (the “Plan Limit”). In addition, on January 1,
2015, and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the Original Plan, the Plan Limit was increased by the lesser of (x) 4% of the number of shares of Common Stock
outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors determined in its discretion.
In March 2019, the Board adopted and the Company’s stockholders approved the Amended and Restated PDS Biotechnology Corporation
2014 Equity Incentive Plan (the “Prior Plan”) which amended and restated the Original Plan in order to remove the annual increase component and which fixed the number of shares of Common Stock authorized for issuance under the Prior Plan to
826,292 shares.
On December 8, 2020, the Board adopted and on June 17, 2021, the stockholders approved, the Second Amended and Restated PDS
Biotechnology Corporation 2014 Equity Incentive Plan (the “Restated Plan”), which amended and restated the Prior Plan. The Restated Plan was identical to the Prior Plan in all material respects, except (a) the number of shares of Common Stock
authorized for issuance under the Restated Plan was increased from 826,292 shares to 4,165,535 shares, plus the total number of shares that remained available for issuance, that were not covered by outstanding awards issued under the Prior
Plan, immediately prior to December 8, 2020; and (b) the Prior Plan was amended to terminate on December 7, 2030, unless earlier terminated.
On May 19, 2023, the Board adopted and on July 14, 2023, the stockholders approved, the Third Amended and Restated PDS
Biotechnology Corporation 2014 Equity Incentive Plan (the “Third Restated Plan”), which amended and restated the Restated Plan to increase the total number of shares authorized for issuance thereunder from 4,165,535 shares to 6,565,535 shares.
On April 28, 2025, the Board adopted and on June 11, 2025, the stockholders approved, an amendment to the Third Restated Plan,
which amendment increased the total amount of shares authorized for issuance under the Third Restated Plan to the sum of (i) 4,165,535 shares of Common Stock, which was the total number of shares of common stock authorized for issuance under
the Restated Plan, plus (ii) 2,400,000 shares of common stock, which reflects the additional shares of common stock authorized by the Board under the Third Restated Plan as of its effective date, plus (iii) 3,144,049 shares of common stock that
were approved at the Company’s 2025 Annual Meeting of Stockholders. As of December 31, 2025, there were 3,741,247 shares available for grant under the Third Restated Plan, as amended.
2018 Stock Incentive Plan
In 2018, the Company’s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares
subject to awards of (i) stock options, (ii) stock appreciation rights, (iii) restricted stock, (iv) deferred stock, (v) stock reload options and/or (vi) other stock-based awards. As of December 31, 2025, there were 190,799 shares available
for grant under the 2018 Stock Incentive Plan.
2019 Inducement Plan
On June 17, 2019, the Board adopted the 2019 Inducement Plan (the “Inducement Plan”) pursuant to which the Company may grant awards of non-qualified stock options. On December 8, 2020, the Company amended the Inducement Plan solely
to increase the total number of shares of common stock reserved for issuance under the Inducement Plan from 200,000 shares to 500,000 shares. On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number
of shares of Common Stock reserved for issuance under the Inducement Plan from 500,000 shares to 1,100,000 shares. On January 22, 2024, the Company further amended the Inducement Plan solely to increase the total number of shares of Common
Stock reserved for issuance under the Inducement Plan from 1,100,000 shares to 2,100,000 shares. The Inducement Plan, and each amendment thereto, was recommended for approval by the Compensation Committee of the Board and subsequently
approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing
Rules, non-qualified stock options under the Inducement Plan may only be made to an employee who has not previously been an employee of the Company or member of the Board of Directors of the Company (or any parent or subsidiary of the Company),
if he or she is granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company
or such subsidiary. As of December 31, 2025, there were 1,087,407 shares available for grant under the Inducement Plan.
Stock Options
Pursuant to the terms of the Third Restated Plan (as amended) and the 2018 Stock Incentive Plan, ISOs granted pursuant to such plans have
a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four-year period. Unless terminated by the Board,
the plans shall continue to remain effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the plans are no longer outstanding.
Our stock option awards have an exercise price at least equal to the fair market value of our common stock on the date of grant and
typically vest as to 25% of the underlying shares on the first anniversary of the date of grant and in equal monthly installments over the following 36 months, subject to the holder’s continued employment with us and potential accelerated
vesting in certain circumstances, including as described below for our named executive officers in the section titled “Employment Agreements.” Our stock option awards granted pursuant to the Third Restated Plan (as amended) and the 2018 Stock
Incentive Plan may be intended to qualify as incentive stock options under the Internal Revenue Code.
In accordance with Item 402(x) of Regulation S-K, we are
providing information regarding our procedures related to the grant of stock options close in time to the release of material non-public information. Neither our Board nor our Compensation Committee takes material non-public information into account when determining the timing of equity awards , nor do we time the disclosure of material non-public information for the purpose of impacting the value of executive compensation .We generally issue equity awards to our executive officers on a limited and infrequent basis, and not in accordance with any fixed schedule.
The following table presents information required by Item
402(x)(2) of Regulation S-K regarding stock options issued to our named executive officers in fiscal year 2025 during the period beginning four business days before and ending one business day after the filing of a current report on Form 8-K that
disclosed material non-public information:
|
|
|
|
|||||||||||
|
Name
|
Grant Date
|
Number of
Securities
Underlying
the award
|
Exercise
Price of
the Award
($/Sh)
|
Grant Date Fair
Value of the
Award
|
Percentage Change in the Closing
Market Price of the Securities
Underlying the Award Between the
Trading Day Ending Immediately
Prior to the Disclosure of Material
Nonpublic Information and the
Trading Day Beginning Immediately
Following the Disclosure of
Material Nonpublic Information
|
||||||||
|
|
6/12/2025
|
|
|
$
|
|
%
|
|||||||
|
|
6/12/2025
|
|
|
$
|
|
%
|
|||||||
|
|
6/12/2025
|
|
|
$
|
|
%
|
Retirement, Health, Welfare and Additional Benefits
Our executive officers are eligible to participate in our employee benefit plans and programs, including medical and dental benefits, flexible spending accounts, short- and
long-term disability and life insurance, to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans. We provide no perquisites or other personal benefits to the named executive officers
that are not available to all full-time employees of the Company.
We sponsor a 401(k) defined contribution plan in which our named executive officers may participate, subject to limits imposed by the
Internal Revenue Code of 1986, as amended, to the same extent as our other full-time employees. Currently, we match 100% of each of our employees’ contributions up to 3% of their salary and 50% of each employee’s contribution between 3% and 5% of
their salary for a maximum contribution of 4% of the applicable employee’s salary. Other than the 401(k) plan, we do not provide any qualified or non-qualified retirement or deferred compensation benefits to our employees, including our named
executive officers.
Employment Agreements
PDS Biotech is a party to employment agreements with each of (i) Dr. Bedu-Addo, effective October 11, 2018, and as amended and
restated on March 14, 2022, (ii) Dr. Shepard, M.D., effective January 22, 2024 and (iii) Mr. Toutain, effective as of May 1, 2024.
The base salary and target bonus for each executive under their respective employment agreements as effective in 2025 are as follows:
|
Executive
|
Base
Salary
|
|
Target Bonus
|
|||
|
Frank Bedu-Addo, Ph.D.
|
$
|
615,322
|
|
Up to 55% of Base Salary
|
||
|
Kirk Shepard, M.D
|
$
|
463,500
|
|
Up to 40% of Base Salary
|
||
|
Stephan Toutain
|
$
|
463,500
|
|
Up to 40% of Base Salary
|
||
If PDS Biotech terminates Dr. Bedu-Addo’s employment without Cause, he resigns for Good Reason (each as defined in the employment agreement), or Dr. Bedu-Addo’s employment is
terminated due to his death, Dr. Bedu-Addo will be entitled to receive accrued benefits including accrued but unpaid salary and bonus, unreimbursed business expenses, and benefits owed under any qualified retirement plan or health and welfare
benefit plan (the “Accrued Obligations”), and the following severance benefits: (i) his base salary for twenty-four (24) months; (ii) bonus equal to the greater of (A) the bonus paid in the prior performance year and (B) the bonus that Dr.
Bedu-Addo would have earned, for the performance year in which the termination occurs, on a prorated basis through the date which he continued to provide services; (iii) outstanding equity held by Dr. Bedu-Addo as of the date of the termination
will become 100% vested and outstanding options will remain exercisable until the earliest of (A) 18 months following the termination date, (B) the original 10-year expiration date for the options, and (C) termination of the equity plan; (iv)
benefits continuation for twenty-four (24) months, paid as supplemental cash compensation in an amount equal to 1.3 times each payment of the expenses paid by Dr. Bedu-Addo for welfare benefit coverage, and (v) in the event of a termination
without Cause or if Dr. Bedu-Addo resigns for Good Reason within ninety (90) days before and twenty-four (24) months following the effective date of a Change in Control (as defined in the employment agreement) (the “Protection Period”), instead
of the bonus referenced in clause (ii) above, Dr. Bedu-Addo will receive a bonus equal to his target annual performance-based cash bonus. If Dr. Bedu-Addo’s employment is terminated for Cause, based on his Disability (as defined in the employment
agreement), or he resigns for any reason other than for Good Reason, he will only receive the Accrued Obligations.
With respect to each of Dr. Shepard and Mr. Toutain, if PDS Biotech terminates the executive’s employment without Cause or the executive resigns for Good Reason (each as
defined in the applicable executive’s employment agreement), he will be entitled to receive the Accrued Obligations and the following severance benefits: (i) base salary for twelve (12) months; (ii) benefits continuation for twelve (12) months,
and (iii) if terminated during the Protection Period, in addition to the base salary and benefits continuation, the executive will also receive a payment equal to his target bonus, and any outstanding equity as of the closing of a Change in
Control (as defined in the applicable executive’s employment agreement) will become 100% vested if the executive’s outstanding equity is assumed or continued by the surviving entity.
In addition, each of the employment agreements for Dr. Bedu-Addo, Dr. Shepard and Mr. Toutain (i) provide that the executive may be eligible for certain grants of equity
awards of common stock of PDS Biotech subject to vesting and other terms and conditions of PDS Biotech’s equity plans and an award agreement, subject to approval of the compensation committee, (ii) provide that if any payment or distribution
would be nondeductible by PDS for federal income tax purposes because of Section 280G of the Internal Revenue Code, PDS Biotech shall reduce the aggregate present value of the payment only if reducing the payment will provide the executive with a
greater net after-tax amount, (iii) provide for certain confidentiality, intellectual property, cooperation, non-competition, non-solicitation and non-disparagement undertakings, and (iii) require the execution and non-revocation of a general
release of claims in favor of PDS Biotech as a condition to receipt of severance benefits.
Outstanding Equity Awards at Fiscal Year-End
The table below sets forth the number of securities underlying outstanding plan awards for each named executive officer as of December 31,
2025. We have omitted the “Stock Awards” columns because our named executive officers did not have any stock awards outstanding at 2025 year-end
|
Number of
Securities
Underlying
Unexercised
Options
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options
Unexercisable(1)
|
Option
Exercise
Price
|
Grant Date
|
|
Expiration
Date
|
Number of
Shares or
Units of
Stock That
Have Not
Vested
|
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested (2)
|
||||||||||||
|
Frank Bedu-Addo, Ph.D.
|
—
|
—
|
—
|
06/12/2025
|
|
—
|
300,000
|
$
|
230,940
|
||||||||||
|
—
|
150,000
|
$1.79
|
06/12/2025
|
|
06/12/2035
|
||||||||||||||
|
138,082
|
161,918
|
$5.87
|
02/28/2024
|
|
02/28/2034
|
||||||||||||||
|
287,919
|
97,381
|
$11.61
|
01/05/2023
|
|
01/05/2033
|
||||||||||||||
|
287,906
|
3,594
|
$6.28
|
01/19/2022
|
|
01/19/2022
|
||||||||||||||
|
707,800
|
—
|
$2.43
|
12/08/2020
|
|
12/08/2030
|
||||||||||||||
|
125,000
|
—
|
$1.45
|
06/23/2020
|
|
06/23/2030
|
||||||||||||||
|
100,000
|
—
|
$5.99
|
06/28/2019
|
|
06/28/2029
|
||||||||||||||
|
53,173
|
—
|
$9.04
|
03/14/2019
|
|
03/14/2029
|
||||||||||||||
|
179,486
|
—
|
$9.04
|
03/14/2019
|
|
03/14/2029
|
||||||||||||||
|
Kirk Shepard, M.D.
|
—
|
—
|
—
|
06/12/2025
|
|
—
|
100,000
|
$
|
76,980
|
||||||||||
|
—
|
150,000
|
$1.79
|
06/12/2025
|
|
06/12/2035
|
||||||||||||||
|
97,123
|
102,877
|
$4.49
|
01/22/2024
|
|
01/22/2034
|
||||||||||||||
|
Stephan Toutain
|
—
|
—
|
—
|
06/12/2025
|
|
—
|
100,000
|
$
|
76,980
|
||||||||||
|
—
|
150,000
|
$1.79
|
06/12/2025
|
|
06/12/2035
|
||||||||||||||
|
83,425
|
116,575
|
$3.61
|
05/24/2024
|
|
05/24/2034
|
||||||||||||||
|
(1)
|
Except as otherwise noted, options vest with respect to one-fourth of the underlying shares on the first anniversary of the grant date and in equal installments of 1⁄36 of the underlying shares on
each monthly anniversary of the grant date thereafter for the subsequent 36 months.
|
|
(2)
|
The amounts in this column are determined by multiplying (i) the number of RSUs shown in the previous column by (ii) $0.7698 (the closing price of the Company’s common stock on December
31, 2025).
|
Director Compensation
In June 2019, we adopted a director compensation policy. The director compensation policy was amended in April 2025, as described below, following a review of the program by
our Compensation Committee. Pursuant to the policy, the annual cash retainer for non-employee directors is $40,000 and the annual cash retainer for the chair of the board of directors is $70,000. Our director compensation policy remained
unchanged in 2025. Annual retainers for committee membership are as follows:
|
Committee
|
Annual
Retainer
|
|||
|
Audit Committee Chairperson
|
$
|
18,500
|
||
|
Audit Committee Member
|
$
|
8,000
|
||
|
Compensation Committee Chairperson
|
$
|
15,000
|
||
|
Compensation Committee Member
|
$
|
7,500
|
||
|
Nominating and Corporate Governance Committee Chairperson
|
$
|
8,000
|
||
|
Nominating and Corporate Governance Committee Member
|
$
|
4,000
|
||
These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any
portion of such quarter that a director is not serving on our board of directors, on such committee or in such position. Non-employee directors are also reimbursed for reasonable out-of-pocket business expenses incurred in connection with
attending meetings of the board of directors and any committee of the board of directors on which they serve and in connection with other business related to the board of directors. Directors may also be reimbursed for reasonable out-of-pocket
business expenses authorized by the board of directors or a committee that are incurred in connection with attending conferences or meetings with management in accordance with a travel policy, as may be in effect from time to time.
In addition to the above fees, the board of directors may determine that additional committee fees are appropriate and should be payable for any newly created committee of
the board of directors.
In addition, pursuant to the changes made to our director compensation policy in April 2025, starting with fiscal year 2025, we grant new non-employee directors upon their
initial election to the board of directors, an option to purchase 22,700 shares of our common stock at an exercise price equal to the closing price of our common stock on the date of grant. Each of these options has a term of 10 years from the
date of the award and 1/3 of these options vest on each of the first, second and third anniversaries of the date of grant, subject to the non-employee director’s continued service as a director. This vesting accelerates as to 100% of the shares
subject to an award upon a change in control of the Company.
Further, pursuant to the changes made to our director compensation policy in April 2025, on the dates of each of our annual meetings of stockholders, each non-employee
director that has served on our board of directors for at least six months automatically receives an option to purchase 22,700 shares of our common stock at an exercise price equal to the closing price of our common stock on the date of the grant
and each non-employee director that has served on our board of directors for less than six months shall receive an option for a pro rata number of shares. Each of these options has a term of 10 years from the date of the award and vest in full on
the first anniversary of the date of grant, subject to the non-employee director’s continued service as a director, with 100% acceleration of vesting upon a change in control of the Company.
The table below summarizes the compensation paid by PDS Biotech to each non-employee director for the year ended December 31, 2025:
|
Name
|
Fees
Earned
Or Paid
in Cash
$
|
Option
Awards
$(1)
|
Total
$
|
|||||||||
|
Gregory Freitag, J.D., CPA(2)
|
62,500
|
26,559
|
(2)
|
89,819
|
||||||||
|
Stephen Glover(3)
|
93,000
|
26,559
|
(4)
|
120,319
|
||||||||
|
Kamil Ali-Jackson, Esq.(4)
|
63,500
|
26,559
|
(5)
|
90,819
|
||||||||
|
Ilian Iliev, Ph.D.(5)
|
40,000
|
26,559
|
(6)
|
67,319
|
||||||||
|
Otis Brawley, M.D.(6)
|
40,000
|
26,559
|
(7)
|
67,319
|
||||||||
|
(1)
|
The amounts shown in this column do not reflect actual compensation received by our directors. The amounts reflect the grant date fair value of option awards and are calculated in
accordance with the provisions of FASB Accounting Standards Codification Topic 718 Compensation - Stock Compensation and assume no forfeiture rate derived in the calculation of the grant date fair value of these awards. Assumptions used
in calculating the value of these awards are included in Note 8, “Stock-Based Compensation” in the notes to the Company’s financial statements included in our most recent Annual Report on Form 10-K. The director will only realize
compensation to the extent the trading price of PDS Biotech’s common stock is greater than the exercise price of such stock options at the time such options are exercised.
|
|
(2)
|
Mr. Freitag was appointed as a director of our Board on March 15, 2019. Mr. Freitag held an aggregate of 87,918 option awards as of December 31, 2025.
|
|
(3)
|
Mr. Glover was appointed to our Board on April 2, 2019. Mr. Glover held an aggregate of 76,700 option awards as of December 31, 2025.
|
|
(4)
|
Ms. Ali-Jackson was appointed to our Board on February 21, 2020. Ms. Ali-Jackson held an aggregate of 70,733 option awards as of December 31, 2025.
|
|
(5)
|
Dr. Iliev was appointed to our Board on April 8, 2020. Dr. Iliev held an aggregate of 65,074 option awards as of December 31, 2025.
|
|
(6)
|
Dr. Brawley was appointed to our Board on November 3, 2020. Dr. Brawley held an aggregate of 67,700 option awards as of December 31, 2025.
|
| ITEM 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
Equity Compensation Plan Information
The following table contains information about our equity compensation plans as of December 31, 2025:
|
|
(A)
|
(B)
|
(C)
|
|||||||||
|
Plan category
|
Number of
securities to be
issued upon
exercise of
outstanding
options,
warrants
and rights
|
Weighted-
average
exercise
price of
outstanding
options,
warrants
and rights
|
Number of
Securities
Remaining
available for
future issuance
under equity
compensation
plans (excluding
securities
reflected
in column (A))
|
|||||||||
|
Equity compensation plans approved by security holders
|
5,792,224
|
(1)
|
$
|
4.19
|
3,741,247
|
|||||||
|
Equity compensation plans not approved by security holders
|
942,800
|
(2)
|
$
|
4.58
|
1,087,407
|
|||||||
|
Total
|
6,735,024
|
$
|
4.55
|
4,828,654
|
||||||||
|
(1)
|
This reflects outstanding stock options (4,992,224) and outstanding RSUs (800,000) issued pursuant to the Third Amended and Restated PDS Biotechnology 2014 Equity Incentive Plan, as
amended.
|
|
(2)
|
This reflects options issued pursuant to the PDS Biotechnology 2019 Inducement Plan, as amended, together with options issued by privately held PDS Biotechnology Corporation (“Private
PDS Biotech”) outside of an equity compensation plan prior to the consummation of the reverse merger with the Private PDS Biotech, pursuant to and in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated
as of November 23, 2018, as amended on January 24, 2019, by and among the Company, Echos Merger Sub, a wholly-owned subsidiary of Edge Therapeutics, Inc. (“Merger Sub”), and Private PDS Biotech, whereby Private PDS Biotech merged with and
into Merger Sub, with Private PDS Biotech surviving as the Company’s wholly owned subsidiary (the “Merger”). In connection with and immediately following completion of the Merger, Edge Therapeutics, Inc. changed its name to PDS
Biotechnology Corporation, and Private PDS Biotech changed its name to PDS Biotech Operating Corporation.
|
Security Ownership of Certain Beneficial Owners and Management
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect
to securities. In accordance with SEC rules, shares of our common stock which may be acquired upon exercise of stock options or warrants which are currently exercisable or which become exercisable within 60 days of the date of the applicable
table below are deemed beneficially owned by the holders of such options and warrants and are deemed outstanding for the purpose of computing the percentage of ownership of such person, but are not treated as outstanding for the purpose of
computing the percentage of ownership of any other person. Subject to community property laws, where applicable, the persons or entities named in the tables below have sole voting and investment power with respect to all shares of our common
stock indicated as beneficially owned by them.
The following table sets forth information with respect to the beneficial ownership of our common stock as of March 31, 2026, by (i) each
stockholder known by us to be the beneficial owner of more than 5% of our common stock (our only classes of voting securities), (ii) each of our directors, (iii) each of our named executive officers and (iv) all of our directors and executive
officers as a group. To the best of our knowledge, except as otherwise indicated, each of the persons named in the table has sole voting and investment power with respect to the shares of our common stock beneficially owned by such person, except
to the extent such power may be shared with a spouse. To our knowledge, none of the shares listed below are held under a voting trust or similar agreement, except as noted.
Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o PDS Biotechnology Corporation, 303A
College Road East, Princeton, NJ 08540.
|
Beneficial
Ownership
|
|||||||
|
Name of Beneficial Owner
|
Shares
|
%(1)
|
|
||||
|
Greater than 5% Stockholders:
|
|||||||
|
-
|
-
|
-
|
|||||
|
PDS Biotech Named Executive Officers and Directors:
|
|||||||
|
Frank Bedu-Addo, Ph.D.(2)
|
2,644,234
|
4.7
|
%
|
||||
|
Gregory Freitag(3)
|
126,431
|
*
|
|||||
|
Stephen Glover(4)
|
132,851
|
*
|
|||||
|
Kamil Ali-Jackson, Esq.(5)
|
59,797
|
*
|
|||||
|
Ilian Iliev, Ph.D.(6)
|
42,374
|
*
|
|||||
|
Otis Brawley, M.D.(7)
|
45,000
|
*
|
|||||
|
Kirk Shepard (8)
|
117,671
|
*
|
|||||
|
Stephan Toutain (9)
|
103,973
|
*
|
|||||
|
All current executive officers and directors as a group (11 persons)
|
4,230,671
|
7.6
|
%
|
||||
* Less than 1%
| (1) |
Percentage ownership is based on 55,815,653 shares of common stock outstanding as of March 31, 2026, together with securities exercisable or convertible into shares of common stock as of May 30, 2026, for
each shareholder. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.
|
| (2) |
Includes 690,866 shares of common stock and 1,953,368 shares subject to outstanding options exercisable within 60 days of March 31, 2026.
|
| (3) |
Includes 61,213 shares of common stock and 65,218 shares subject to outstanding options exercisable within 60 days of March 31, 2026.
|
| (4) |
Includes 78,851 shares of common stock and 54,000 shares subject to outstanding options exercisable within 60 days of March 31, 2026.
|
| (5) |
Includes 11,764 shares of common stock and 48,033 shares subject to outstanding options exercisable within 60 days of March 31, 2026.
|
| (6) |
Includes 42,374 shares subject to outstanding options exercisable within 60 days of March 31, 2026.
|
| (7) |
Includes 45,000 shares subject to outstanding options exercisable within 60 days of March 31, 2026.
|
| (8) |
Includes 117,671 shares subject to outstanding options exercisable within 60 days of March 31, 2026.
|
| (9) |
Includes 103,973 shares subject to outstanding options exercisable within 60 days of March 31, 2026.
|
Certain Relationships and Related Transactions
Other than employment agreements with our named executive officers and other payments made to our named executive officers, all as
described above under Item 11 in the section entitled “Executive Compensation” and compensation paid to directors as described above under Item 11 in the section titled “Director Compensation” there were no transactions since January 1, 2025 or
any currently proposed transactions, to which PDS Biotech has been a participant, in which:
|
●
|
the amounts exceeded or will exceed the lesser of $120,000 and 1% of the average of our total assets at year-end for the fiscal years ended December 31, 2025 and 2024; and
|
|
●
|
any of the directors, executive officers or holders of more than 5% of the respective capital stock, or any member of the immediate family of the foregoing persons, had or will have a
direct or indirect material interest.
|
Our Audit Committee is charged with the responsibility of reviewing and approving all related person transactions (as defined in SEC
regulations), and periodically reassessing any related person transaction entered into by PDS Biotech to ensure continued appropriateness. This responsibility is set forth in our Audit Committee charter. A related party transaction will only be
approved if the members of the Audit Committee determine that the transaction is in the best interests of PDS Biotech. If a director is involved in the transaction, he or she will recuse himself or herself from all decisions regarding the
transaction. In addition, the Audit Committee will review these transactions under our Code of Conduct, which governs conflicts of interests, among other matters, and is applicable to our employees, officers and directors.
Director Independence
Please refer to the disclosure in Item 11 under the heading “Director Independence.”
The following table represents aggregate fees billed to PDS Biotech for the fiscal years ended December 31, 2025 and 2024, by KPMG
LLP, PDS Biotech’s independent registered public accounting firm.
|
|
Fiscal
Year
Ended
2025
|
Fiscal
Year
Ended
2024
|
||||||
|
Audit Fees
|
$
|
1,024,224
|
$
|
940,000
|
||||
|
Audit-Related Fees
|
—
|
—
|
||||||
|
Tax Fees
|
—
|
—
|
||||||
|
All Other Fees
|
—
|
—
|
||||||
|
Total Fees
|
$
|
1,024,224
|
$
|
940,000
|
||||
Audit fees: Audit fees consist of fees associated with the annual audit of our financial statements, the reviews of our interim
financial statements, fees consist of fees incurred in connection with the issuance of consent and comfort letters in connection with registration statement filings with the SEC and all services that are normally provided by the accounting firm
in connection with statutory and regulatory filings or engagements.
Audit-related fees: Audit-related fees includes fees for services that are traditionally performed by the auditor such as audits of
employee benefit plans sponsored by the Company, due diligence assistance, SOC engagements, audits of financial statements of a carve-out entity in anticipation of a subsequent divestiture and other attest services.
Tax fees: Tax fees consist of fees for tax services, including tax compliance, and related expenses.
All KPMG LLP services and fees in the fiscal years ended December 31, 2025 and 2024 were pre-approved by the Audit Committee or its properly delegated authority.
Pre-Approval Policies and Procedures
The Audit Committee pre-approves audit and non-audit services rendered by our independent registered public accounting firm, KPMG LLP. The
Audit Committee pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of the Audit Committee’s approval of the scope of
the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee’s
members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.
If KPMG LLP renders services other than audit services to us, the Audit Committee will determine whether the rendering of these services
is compatible with maintaining KPMG LLP’s independence.
PART IV
| ITEM 15. |
Exhibits, Financial Statement Schedules
|
The list of exhibits filed with this Amendment is set forth in the Exhibit Index below. For the remainder of the exhibits, please refer to the Original Form 10-K.
|
Exhibit
Number
|
Exhibit Description
|
|
|
Principal Executive Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2005.
|
||
|
Principal Financial Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2005.
|
|
101.INS*
|
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
the Inline XBRL document)
|
|
|
101.SCH*
|
Inline XBRL Taxonomy Extension Schema Document
|
|
|
101.DEF*
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
101.LAB*
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
|
|
101.PRE*
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
* Filed herewith.
Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Form 10-K/A to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
PDS Biotechnology Corporation
|
||
|
April 28, 2026
|
By:
|
/s/ Frank Bedu-Addo
|
|
Frank Bedu-Addo, Ph.D.
|
||
|
President and Chief Executive Officer
|
||
|
April 28, 2026
|
By:
|
/s/ Lars Boesgaard
|
|
Lars Boesgaard
|
||
|
Chief Financial Officer
|
||
28